Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update
Source : https://www.frontiersin.org/articles/10.3389/fphar.2022.1064472/full
Protein kinases are enzymes that transfer phosphate to protein, resulting in the modification of the protein. The human genome encodes approximately 538 kinases. Kinases play a role in maintaining a...
Conclusions: In this review, we discuss FDA-approved kinase inhibitors and their mechanism, clinical benefits, and side effects, as well as the challenges of overcoming some of their side effects and future prospects for new kinase inhibitor discovery.
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36626914/
Waldenström macroglobulinaemia (WM) is characterized by the presence of a MYD88 L265P mutation. This mutation promotes growth and survival of malignant cells through Bruton tyrosine kinase (BTK) activation. Ibrutinib was...
Conclusions: These data suggest that dose reduction of ibrutinib is a reasonable treatment approach for patients with intolerable side effects.
BTK inhibitor combined with anti‑PD‑1 monoclonal antibody for the treatment of CD20‑negative primary central nervous system lymphoma: A case report
Source : https://www.spandidos-publications.com/10.3892/ol.2022.13634
CD20‑negative diffuse large B‑cell lymphoma (DLBCL) is a rare type of lymphoproliferative disorder characterized by a high degree of aggressiveness, a tendency for extranodal invasion and chemotherapeutic resistance. CD20‑negative DLBCL...
Conclusions: The present case report and literature review show that a combination of drugs targeting different mechanisms may be used to treat PCNSL to prolong patient survival time. The mechanism of the enhanced efficacy of a combination of the two drugs may be related to the enhancement of antitumor T‑cell immune responses and reversal of...
Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36669145/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: PBM-GVH mismatches inform mortality risks after single class I HLA-mismatched UD-HCT, suggesting that prospective consideration of directional PBM-matching status might improve outcome. These findings highlight immunopeptidome divergence between mismatched HLA as a driver of clinical tolerability in UD-HCT."
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36675328/
Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent a recognized option for the treatment of patients affected by indolent B cell lymphomas. However, small molecules as single...
Conclusions: Conclusi9ons/Relevance: Considering the early safety data from clinical trials, our study identifies the IRAK4 inhibitor emavusertib as a novel compound to be explored in trials for patients with MYD88-mutated indolent B cell lymphomas as single agent and as combination partner with BTK or PI3K inhibitors in unselected populations...